News|Articles|November 16, 2026

Onvansertib Earns FDA Fast Track Designation in First-Line RAS-Mutated mCRC

Author(s)OncLive Staff
Fact checked by: Riley Kandel
Listen
0:00 / 0:00

Key Takeaways

  • Fast track designation was supported by phase 2 randomized data showing markedly higher confirmed ORR with onvansertib plus FOLFIRI/bevacizumab than chemotherapy/bevacizumab alone.
  • Median PFS remained unreached on the onvansertib combination at the September 2026 cutoff, while pooled standard-of-care arms approximated 11 months.
SHOW MORE

Onvansertib plus FOLFIRI/bevacizumab earned fast track status in first-line KRAS- or NRAS-mutated metastatic colorectal cancer.

The FDA has granted fast track designation to onvansertib plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) and bevacizumab (Avastin) as frontline therapy for adults with KRAS- or NRAS-mutated metastatic colorectal cancer (mCRC).¹

Findings from the ongoing randomized phase 2 CRDF-004 trial (NCT06106308) supported the designation. In the intent-to-treat population, the combination yielded a confirmed objective response rate (ORR) of 72.2% compared 42.1% with FOLFIRI plus bevacizumab alone. As of a September 28, 2026, the median progression-free survival (PFS) had not been reached in with the combination vs approximately 11 months across the pooled standard-of-care arms. Every patient still receiving the onvansertib-based combination had been treated for 21 months or longer.

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and fast track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, president and chief executive officer of Cardiff Oncology in a news release. “Our randomized Phase 2 data give us confidence that onvansertib may provide an additive benefit to the current standard-of-care, as reflected in the maturing data from the ongoing trial.”

Notably, onvansertib previously received FDA orphan drug designations in chronic myelomonocytic leukemia (CMML) in October 2026 and in small cell lung cancer in November 2026.2

How was the phase 2 CRDF-004 trial designed?

Onvansertib Fast Track: Highlights

  • Fast track designation has been granted to onvansertib plus FOLFIRI and bevacizumab for patients KRAS- or NRAS-mutated mCRC in the first line setting
  • The agent produced an ORR of 72.2% in the intention-to-treat population
  • Onvansertib has already received orphan drug designations in CMML and SCLC

The randomized, open-label trial that enrolled 110 patients with histologically confirmed mCRC, a documented KRAS or NRAS mutation, and no prior systemic therapy for metastatic disease.3 Patients also needed an ECOG performance status of 0 or 1 and acceptable organ function.

The trial excluded patients whose tumors also carried a BRAF V600 mutation or were microsatellite instability–high or mismatch repair–deficient. Patients with prior exposure to a VEGF inhibitor, such as bevacizumab or a biosimilar, and patients with untreated or symptomatic brain metastases were also excluded.

Patients were randomly assigned to oral onvansertib at 20 mg or 30 mg, both given on days 1 through 5 and 15 through 19 of 28-day cycles, plus either FOLFIRI and bevacizumab or leucovorin, fluorouracil, and oxaliplatin (FOLFOX) plus bevacizumab. The comparator arms received the matching chemotherapy plus bevacizumab backbone without onvansertib. Chemotherapy and bevacizumab were given on days 1 and 15 of every 28-day cycle.

The primary end point of the trial is ORR per RECIST 1.1 criteria by blinded independent central review. Secondary end points include PFS, duration of response, disease control rate, overall survival, and safety. Enrollment began in February 2024 at US sites, and the trial is no longer recruiting.

The data that supported the approval was from the group of patients who received onvansertib at 30 mg plus FOLFIRI and bevacizumab, importantly, this regimen has been proposed for phase 3 testing.

What previous data was shown for onvansertib in CMML?

The previous orphan drug designation for onvansertib in CMML followed data from an investigator-sponsored phase 1 dose-escalation trial (NCT05549661) evaluating onvansertib monotherapy in patients with relapsed/refractory myeloproliferative CMML.2

In the trial (n = 9), onvansertib was relatively well tolerated and showed early signs of activity in approximately 40% of patients. Clinical benefit was observed in 3 patients, of those, 1 patient had a 100% platelet response, 1 had normalization of white blood cell (WBC) count from a baseline WBC count higher than 50 × 10⁹/L, and 1 had a spleen response. At a 9-mg/m² dose, 1 patient achieved an optimal marrow response, with bone marrow blasts falling from 8% to 2%; this allowed the patient to proceed to allogeneic hematopoietic stem cell transplant. Another 3 patients had stable disease.

References

  1. Cardiff Oncology receives FDA fast track designation for onvansertib in first-line RAS-mutated metastatic colorectal cancer. News release. Cardiff Oncology. November 16, 2026. Accessed November 16, 2026. https://www.globenewswire.com/news-release/2026/11/16/3403351/0/en/cardiff-oncology-receives-fda-fast-track-designation-for-onvansertib-in-first-line-ras-mutated-metastatic-colorectal-cancer.html
  2. Cardiff Oncology receives FDA orphan drug designation for onvansertib in chronic myelomonocytic leukemia. News release. Cardiff Oncology. October 21, 2026. Accessed November 16, 2026. https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-receives-fda-orphan-drug-designation
  3. Study of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab versus FOLFIRI and bevacizumab or FOLFOX and bevacizumab for first-line treatment of metastatic colorectal cancer in adult participants with a KRAS or NRAS mutation. ClinicalTrials.gov. Updated November 10, 2026. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT06106308

Related to this article